AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time.
| Event details follow: | |
| Date: | Thursday, August 8th |
| Time: | 8:30 a.m. Eastern Time |
| Audio Webcast: | https://www.CassavaSciences.com/company-presentations |
| Or | |
| Audio Webcast: | https://edge.media-server.com/mmc/p/zjvmjjcr |
A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences’ website for 90 days following the webcast.
About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our novel science is based on stabilizing—but not removing—a critical protein in the brain.
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450 or This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.81 |
| Daily Change: | -0.21 -6.95 |
| Daily Volume: | 3,609,595 |
| Market Cap: | US$135.190M |
November 25, 2024 November 07, 2024 September 24, 2024 September 09, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
